The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

Deutsche Bank (ETR:DBKGn) initiated coverage on shares of Biohaven Pharmaceutical (TADAWUL:2070) Holding (NYSE:BHVN) with a Buy rating and a price target of $65.00. The firm's analysts cited the ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Florida's Medicaid Fraud Control Unit secured the win through a multistate action. "Actions, like those alleged here, must be ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...

Pharma giant Pfizer has agreed to pay $59 million to settle a federal lawsuit accusing a local biopharmaceutical company of ...

The Michigan Attorney General’s Office says the state has joined 37 other states and the territory of Puerto Rico in the ...

A coalition consisting of the U.S. Department of Justice, 37 states, and Puerto Rico, filed suit against Biohaven ...

California Attorney General Bonta announced a settlement against Pfizer (PFE)-owned Biohaven Pharmaceutical “for submitting false claims to the ...

Michigan has joined the U.S. Department of Justice, 37 other states and Puerto Rico in settling kickback allegations against a Pfizer, Inc. subsidiary. Pfizer has agreed to ...

California Attorney General Announces Nearly $60 Million Settlement Against Pfizer-Owned Pharmaceutical Holding Company, ...